Piyush Gupta1, Pooja Dewan, Dheeraj Shah, Nisha Sharma, Nidhi Bedi, Iqbal R Kaur, Ajay Kumar Bansal, S V Madhu. 1. Department of Pediatrics; *Department of Microbiology; $Department of Biostatistics and Medical Informatics; and #Division of Endocrinology, Department of Medicine; University College of Medical Sciences and Guru Teg Bahadur Hospital, Delhi, India. Correspondence to: Dr Piyush Gupta, Professor of Pediatrics, University College of Medical Sciences and Guru Teg Bahadur Hospital, Dilshad Garden, Delhi 110 095, India. prof.piyush.gupta@gmail.com.
Abstract
OBJECTIVE: To evaluate the efficacy of single oral mega-dose of Vitamin D3 for treatment and prevention of pneumonia in under-five children. DESIGN: Randomized, double blind, placebo-controlled trial. SETTING: Tertiary-care hospital. PARTICIPANTS: 324 children (of 980 assessed) between 6 mo-5 y age (median (IQR): 12 (7,19.8) mo) with WHO-defined severe pneumonia. Of these, 126 (39%) were vitamin D deficient (serum 25(OH)D <12 ng/mL). INTERVENTION: 100,000 IU of oral cholecalciferol (n= 162) or placebo (n= 162) in single dose, administered at enrolment. Outcome variables: Primary: Time to resolution of severe pneumonia and proportion of children having recurrence of pneumonia in next 6 months; Secondary: Change in serum levels of 25(OH)D; immunoglobulins IgA, IgG, IgM, and cathelicidin 2 weeks following supplementation; and time taken for overall resolution of illness. OUTCOME VARIABLES: Primary: Time to resolution of severe pneumonia and proportion of children having recurrence of pneumonia in next 6 months; Secondary: Change in serum levels of 25(OH)D; immunoglobulins IgA, IgG, IgM, and cathelicidin 2 weeks following supplementation; and time taken for overall resolution of illness. RESULTS: Median (95% CI) time for resolution of severe pneumonia was 30 (29, 31) h in the vitamin D group as compared to 31 (29,33) h in the placebo group [adjusted hazard ratio (95% CI): 1.39 (1.11, 1.76); P = 0.005]. The risk of recurrence of pneumonia in next 6 months was comparable in the two groups [placebo: 36/158 (22.8%); vitamin D: 39/156 (25%); RR (95% CI): 1.13 (0.67,1.90); P 0.69]. Proportion of vitamin D deficient children declined from 38% to 4% in the supplementation group, and from 41% to 33% in the placebo group, two weeks after supplementation. There was no significant effect of vitamin D supplementation on serum levels of cathelicidin, IgA and IgG. The time taken for complete recovery from pneumonia, duration of hospitalization, and fever clearance time were comparable for the two groups. No adverse event was noted related to the intervention. CONCLUSION: There is no robust evidence of a definite biological benefit, either for therapy or prevention, to suggest a routine megadose supplement of vitamin D3 for under-five children with severe pneumonia.
RCT Entities:
OBJECTIVE: To evaluate the efficacy of single oral mega-dose of Vitamin D3 for treatment and prevention of pneumonia in under-five children. DESIGN: Randomized, double blind, placebo-controlled trial. SETTING: Tertiary-care hospital. PARTICIPANTS: 324 children (of 980 assessed) between 6 mo-5 y age (median (IQR): 12 (7,19.8) mo) with WHO-defined severe pneumonia. Of these, 126 (39%) were vitamin D deficient (serum 25(OH)D <12 ng/mL). INTERVENTION: 100,000 IU of oral cholecalciferol (n= 162) or placebo (n= 162) in single dose, administered at enrolment. Outcome variables: Primary: Time to resolution of severe pneumonia and proportion of children having recurrence of pneumonia in next 6 months; Secondary: Change in serum levels of 25(OH)D; immunoglobulins IgA, IgG, IgM, and cathelicidin 2 weeks following supplementation; and time taken for overall resolution of illness. OUTCOME VARIABLES: Primary: Time to resolution of severe pneumonia and proportion of children having recurrence of pneumonia in next 6 months; Secondary: Change in serum levels of 25(OH)D; immunoglobulins IgA, IgG, IgM, and cathelicidin 2 weeks following supplementation; and time taken for overall resolution of illness. RESULTS: Median (95% CI) time for resolution of severe pneumonia was 30 (29, 31) h in the vitamin D group as compared to 31 (29,33) h in the placebo group [adjusted hazard ratio (95% CI): 1.39 (1.11, 1.76); P = 0.005]. The risk of recurrence of pneumonia in next 6 months was comparable in the two groups [placebo: 36/158 (22.8%); vitamin D: 39/156 (25%); RR (95% CI): 1.13 (0.67,1.90); P 0.69]. Proportion of vitamin D deficient children declined from 38% to 4% in the supplementation group, and from 41% to 33% in the placebo group, two weeks after supplementation. There was no significant effect of vitamin D supplementation on serum levels of cathelicidin, IgA and IgG. The time taken for complete recovery from pneumonia, duration of hospitalization, and fever clearance time were comparable for the two groups. No adverse event was noted related to the intervention. CONCLUSION: There is no robust evidence of a definite biological benefit, either for therapy or prevention, to suggest a routine megadose supplement of vitamin D3 for under-five children with severe pneumonia.
Authors: Sandy Slow; Michael Epton; Malina Storer; Rennae Thiessen; Steven Lim; James Wong; Paul Chin; Pleayo Tovaranonte; John Pearson; Stephen T Chambers; David R Murdoch Journal: Sci Rep Date: 2018-09-14 Impact factor: 4.379
Authors: Fahmida Chowdhury; Abu Sadat Mohammad Sayeem Bin Shahid; Mosharrat Tabassum; Irin Parvin; Probir Kumar Ghosh; Mohammad Iqbal Hossain; Nur Haque Alam; A S G Faruque; Sayeeda Huq; Lubaba Shahrin; Nusrat Homaira; Zakiul Hassan; Zubair Akhtar; S Mah-E-Muneer; George J Fuchs; Tahmeed Ahmed; Mohammod Jobayer Chisti Journal: PLoS One Date: 2021-02-19 Impact factor: 3.240
Authors: Daniel E Roth; Steven A Abrams; John Aloia; Gilles Bergeron; Megan W Bourassa; Kenneth H Brown; Mona S Calvo; Kevin D Cashman; Gerald Combs; Luz María De-Regil; Maria Elena Jefferds; Kerry S Jones; Hallie Kapner; Adrian R Martineau; Lynnette M Neufeld; Rosemary L Schleicher; Tom D Thacher; Susan J Whiting Journal: Ann N Y Acad Sci Date: 2018-09-18 Impact factor: 5.691